The China MedTech Edge: January 2026 Intelligence Briefing

Delivering essential intelligence on China’s MedTech ecosystem: Policy & Compliance, Innovation, Global Strategy and beyond.

February 1, 2026

As the “15th Five-Year Plan” commences, January 2026 has witnessed significant momentum in China’s medical device sector, characterized by refined regulatory standards, accelerated domestic innovation e.g., in high-end imaging, and active investment in domestic medtech innovations.

1. Regulatory and Policy Landscape

  • National Standardization Program: The National Medical Products Administration (NMPA) has initiated the selection process for 80 new medical device industry standards and two foreign language editions for 2026. This move is aimed at aligning domestic technical requirements with international benchmarks to support high-quality development.
  • Service Pricing Reform: New national guidelines for “Surgery and Treatment Auxiliary Operations” have been established to standardize pricing for robot-assisted and remote surgeries. This creates a transparent framework for reimbursement, moving beyond traditional application-based pricing.
  • VBP Expansion: The sixth batch of high-value medical consumable centralized volume-based procurement (VBP) concluded on January 14, targeting drug-coated balloons and urinary intervention products. Over 440 products from 202 suppliers were selected, further driving the trend of domestic substitution in interventional consumables.

2. Latest Medical Device Approvals

According to official data from the National Medical Products Administration (NMPA), a total of seven innovative medical devices were approved for market launch through the Green Channel in January 2026. These products span four cutting-edge sectors: AI-assisted diagnosis, high-end imaging, vascular intervention, and minimally invasive surgery, as seen the selected approvals below:

2.1 Self-Expanding Intrasaccular Aneurysm Embolization Device (MicroMedTec): This high-density, self-expanding mesh is woven from ultra-fine nitinol and nitinol alloy wires. It provides high visibility while utilizing structural support to fix itself within the aneurysm and cover the neck. It is indicated for the endovascular treatment of small-to-medium sized, wide-necked unruptured intracranial bifurcation aneurysms (diameters 2.8mm–12.51mm) in locations such as the middle cerebral artery and basilar artery tip.

2.2 Urothelial Cancer Chromosomal Abnormality Detection Kit (Prophet Genomics): Utilizing Joint Probe Anchoring Polymerization Sequencing, this domestic-first kit qualitatively detects chromosomal duplications and deletions in human urine samples. It provides a non-invasive auxiliary diagnostic alternative for patients suspected of having urothelial cancer.

2.3 X-ray Computed Tomography System (United Imaging): This system is China’s first CT to feature dual-source and dual-wide-body detector technology. By offering broad volume coverage and high temporal resolution, it significantly enhances cardiac scanning capabilities and reduces procedural requirements for patients during coronary CT angiography and spectral imaging.

2.4 Disposable Peripheral Vascular Thrombectomy Catheter (Genetide): This domestic-first device is designed for the percutaneous endovascular removal of acute, subacute, and chronic thrombi in peripheral arteries. It utilizes magnetic coupling transmission and a dual-blade configuration to offer simpler and more efficient operation compared to traditional debulking methods.

2.5 Disposable Intracardiac Echocardiography (ICE) Imaging Catheter (MicroPort EP): Integrated with magnetic positioning, this catheter provides high-definition real-time imaging of cardiac structures and large vessels. When used with 3D mapping systems, it enables ultrasound modeling and provides spatial positioning data, offering clinicians comprehensive intraoperative information.

3. Market Dynamics and Investment

  • Capital Market Sentiment: January saw a rebound in sector investment, with a focus on core component breakthroughs and global solution providers. The pharmaceutical and medical device sector is now forecast to generate over $2.1 trillion in annual revenue by 2030.
  • Retail Market Growth: The out-of-hospital medical device market is projected to reach 500 billion RMB by the end of 2026, driven by an aging population and the expansion of smart health management systems for chronic diseases like diabetes.

4. Critical Clinical Trends

The medical device sector is shifting from “price suppression” to “innovation-driven” growth. Clinical focus has intensified on minimally invasive technologies and refined anatomical access—evidenced by the launch of smaller-diameter catheters that improve maneuverability in restricted spaces like the left atrium. Furthermore, data-driven care models, supported by real-time spatial data and 3D mapping, are becoming the standard for high-end cardiac interventions.